Affiliated with a Castle Connolly Top Hospital
Who is Dr. Hoppe, Radiation Oncologist in Pleasanton, CA?
Dr. Richard Hoppe, MD is a Radiation Oncologist, who primarily practices in Pleasanton, CA with 2 additional practice locations. He is board certified. Dr. Hoppe completed his residency at Stanford Univ Hosp, Therapeutic Radiology North Shore Univ Hosp, Internal Medicine. Dr. Hoppe is fluent in English, and is currently seeing new patients. Dr. Hoppe’s practice accepts Kaiser Permanente, Medicaid, Medicare and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Hoppe’s office.
What are Areas of Expertise for Dr. Hoppe?
Dr. Richard Hoppe, MD is a highly-rated, board-certified Radiation Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Hoppe empowers patients to confidently navigate their health journey, specializing in Cutaneous Lymphoma, Hodgkin's Lymphoma, Lymphoma, and comprehensive wellness support. Serving the Pleasanton, CA community, Dr. Hoppe is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Hoppe go to medical school and complete their residency?
Residency: Stanford Univ Hosp, Therapeutic Radiology North Shore Univ Hosp, Internal Medicine | Stanford University School of Medicine
Is Dr. Hoppe board certified as a Radiation Oncologist?
Yes, Dr. Richard Hoppe, MD is board certified by the American Board of Radiology , American Board of Radiology since 1976
What languages does Dr. Hoppe speak?
Dr. Hoppe and their clinical team can communicate with patients in the following languages:
English
What conditions does a Radiation Oncologist like Dr. Hoppe typically treat?
As a Radiation Oncologist, Dr. Hoppe diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Hoppe. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Mycosis Fungoides
- MALT Lymphoma
- Lymphoma
- Mycosis fungoides
- Cutaneous T-cell lymphoma
- CTCL
- Alibert-Bazin syndrome
- Mucosa-associated lymphoid tissue lymphoma
- Extranodal marginal zone lymphoma
- B-cell lymphoma
ICD-10 Codes:
- C8409: Mycosis fungoides, extranodal and solid organ sites
- C884: Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]
Also known as:
- Multiple Myeloma
- Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment (PDQ®)
- Active multiple myeloma
- Untreated multiple myeloma
- Plasma cell myeloma
ICD-10 Codes:
- C9000: Multiple myeloma not having achieved remission
Also known as:
- Acute Myeloid Leukemia in Remission
- Acute Myeloid Leukemia
- AML Leukemia in Remission
- Acute Myeloblastic Leukemia in Remission
- Acute Myelogenous Leukemia in Remission
ICD-10 Codes:
- C9201: Acute myeloblastic leukemia, in remission
What procedures does a Radiation Oncologist like Dr. Hoppe typically perform?
As a Radiation Oncologist, procedures performed by Dr. Richard Hoppe may include:
- Abdominal Aortic Aneurysm (AAA) Screening
- Abdominal Imaging
- Abdominal Radiology Consultation
- Angiography
- Arthrography
- Barium Swallow
- Bone Biopsy
- Bone Density Measurement / DXA Scan
Please contact Dr. Hoppe's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Hoppe accept my insurance?
Dr. Hoppe accepts most major insurance plans. Important: Please call our office at before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Hoppe accept in Pleasanton, CA?
Dr. Hoppe in Pleasanton, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
Care N' Care Insurance Company
CVS Health (formerly Aetna)
Federal government of the United States
Kaiser Permanente
Medicaid
Medicare
State of California
UnitedHealth Group
View All Insurances
Where is Dr. Hoppe's office located?
Recognitions
Publications
STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS
, 2011
REVISITING LOW-DOSE TOTAL SKIN ELECTRON BEAM THERAPY IN MYCOSIS FUNGOIDES
, 2011
In Situ Vaccition With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
, 2010
Cutaneous Peripheral T-Cell Lymphoma Associated With a Proliferation of B Cells
, 2009
Prognostic Factors in Primary Cutaneous Apl
, 2009
Low Stage Follicular Lymphoma
, 2009
Dymic CD8 T-Cell Responses to Tumor
, 2009
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
, 2008
Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease
, 2008
Hodgkin disease/lymphoma.
, 2008
Tolerance and chimerism after rel and hematopoietic-cell transplantation.
, 2008
Impact of positive positron emission tomography on prediction of freedom from progression after
, 2007
Revised response criteria for malignt lymphoma
, 2007
Screening for corory artery disease after mediastil irradiation for Hodgkin's disease
, 2007
Second lymphomas and other malignt neoplasms
, 2007
Protective conditioning for acute graft-versus-host disease
, 2005
A technique of bone marrow collection from vertebral bodies of cynomolgus macaques
, 2005
Expression of the bcl-6 and MUM1
, 2005
Short tandem repeat alysis to monitor chimerism in Macaca fascicularis
, 2004
Extranodal nonorbital indolent lymphomas of the head and neck
, 2004
CD30(+) cutaneous lymphoproliferative disorders
, 2003
Rituximab in lymphocyte-predomint Hodgkin disease: results of a phase 2 trial
, 2003
Gene expression profiles of cutaneous B cell lymphoma
, 2003
Topical nitrogen mustard in the magement of mycosis fungoides - Update of the Stanford experience
, 2003
Hodgkin's disease: A model for interdiscipliry cancer magement: 2002 Janeway Lecture
, 2002
Long-term follow-up after total lymphoid irradiation in pediatric heart transplant recipients
, 2002
Primary radiotherapy for localized orbital malt lymphoma
, 2002
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease
, 2002
tural killer/tural killer
, 2001
Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides
, 2001
Long-term follow-up of patients with Stage III follicular lymphoma treated with primary
, 2001
Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced
, 2000
Magement of breast cancer after Hodgkin's disease
, 2000
What is the significance of sal involvement in sopharyngeal carcinoma?
, 1999
The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects.
, 1999
Epidermotropic cutaneous B-cell lymphoma mimicking mycosis fungoides
, 1999
Mycosis fungoides and the Sezary syndrome
, 1999
Results of the 1988-1989 patterns of care study process survey for Hodgkin's disease
, 1999
Role of histology in providing prognostic information in mycosis fungoides
, 1998
Mycosis fungoides in young patients: Clinical characteristics and outcome
, 1998
Radiation therapy as a component of high-dose salvage strategies in Hodgkin's disease.
, 1998
Fractioted total-body irradiation, etoposide
, 1997
Long-term depletion of ive T cells in patients treated for Hodgkin's disease
, 1997
Non-Hodgkin's lymphoma of the parasal sinuses
, 1997
Stanford-Kaiser permanente G1 study for clinical stage I to IIA Hodgkin's disease
, 1997
Comparison between conventiol salvage therapy
, 1997
Over 20 Years of Progress in Radiation Oncology: Hodgkin's Disease.
, 1997
Gastrointestil cancer after treatment of Hodgkin's disease
, 1997
Clinical stage IA (limited patch and plaque) mycosis fungoides - A long-term outcome alysis
, 1996
High-dose therapy and autologous bone marrow transplantation for relapsed
, 1996
Is radiotherapy curative for stage I
, 1996
Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclol antibody
, 1996
Long-Term Complications of Treatment and Causes of Mortality After Hodgkin's Disease.
, 1996
MULTIPLE COURSES OF HIGH-DOSE TOTAL SKIN ELECTRON-BEAM THERAPY IN THE MAGEMENT OF MYCOSIS-FUNGOIDES
, 1995
PELVIC RELAPSE FOLLOWING SUBTOTAL LYMPHOID IRRADIATION IN EARLY-STAGE HODGKINS
, 1995
BRIEF CHEMOTHERAPY, STANFORD-V
, 1995
CD8-POSITIVE TUMOR-INFILTRATING LYMPHOCYTES INFLUENCE THE LONG-TERM SURVIVAL OF PATIENTS WITH
, 1995
FRACTIOTED TOTAL-BODY IRRADIATION, ETOPOSIDE
, 1994
TREATMENT OF EARLY-STAGE GASTRIC LYMPHOMA
, 1994
EFFECT OF TREATMENT FOR HODGKINS-DISEASE ON PULMORY-FUNCTION - RESULTS OF A PROSPECTIVE-STUDY
, 1994
EFFECT OF FILGRASTIM (G-CSF) IN HODGKINS-DISEASE PATIENTS TREATED WITH RADIATION
, 1994
FACTORS AFFECTING LATE MORTALITY FROM HEART-DISEASE AFTER TREATMENT OF HODGKINS-DISEASE
, 1993
CARDIAC DISEASE FOLLOWING TREATMENT OF HODGKINS-DISEASE IN CHILDREN AND ADOLESCENTS
, 1993
MR-IMAGING TO DETECT CHEST
, 1993
HODGKINS-DISEASE WITH BULKY MEDIASTIL INVOLVEMENT
, 1993
MYCOSIS-FUNGOIDES - CLINICAL AND HISTOLOGIC FEATURES, STAGING
, 1993
BREAST-CANCER AFTER TREATMENT OF HODGKINS-DISEASE
, 1993
THE STANFORD EXPERIENCE WITH COMBINED PROCARBAZINE
, 1992
THE MAGEMENT OF HODGKINS-DISEASE IN RELAPSE AFTER PRIMARY RADIATION-THERAPY
, 1992
METASTATIC CARCINOMA IN LYMPH-NODES SIMULATING SYNCYTIAL VARIANT OF NODULAR SCLEROSING HODGKINS
, 1991
THE MAGEMENT OF MYCOSIS-FUNGOIDES AT STANFORD - STANDARD AND INNOVATIVE TREATMENT PROGRAMS
, 1991
TOTAL LYMPHOID IRRADIATION FOR TREATMENT OF INTRACTABLE CARDIAC ALLOGRAFT-REJECTION
, 1991
OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLOL
, 1991
THE STANFORD EXPERIENCE WITH HIGH-DOSE ETOPOSIDE CYTOREDUCTIVE REGIMENS AND AUTOLOGOUS BONE
, 1991
TOTAL SKIN ELECTRON-BEAM THERAPY IN THE MAGEMENT OF MYCOSIS-FUNGOIDES
, 1991
RADIATION-THERAPY IN THE MAGEMENT OF HODGKINS-DISEASE
, 1990
DISCORDANT EXPRESSION OF ANTIGENS BETWEEN INTRAEPIDERMAL AND INTRADERMAL T-CELLS IN MYCOSIS
, 1990
RADIATION-THERAPY IN THE MAGEMENT OF BULKY MEDIASTIL HODGKINS-DISEASE
, 1990
LEU-8/CD7 ANTIGEN EXPRESSION BY CD3+ T-CELLS - COMPARATIVE-ALYSIS OF SKIN AND BLOOD IN
, 1990
PROGNOSTIC FACTORS FOR PATIENTS RELAPSING AFTER RADIOTHERAPY FOR EARLY-STAGE HODGKINS-DISEASE
, 1990
Bone marrow transplantation for hematologic maligncies: the Stanford experience.
, 1990
CUTANEOUS LYMPHOID HYPERPLASIA
, 1989
OUTCOME OF THE ACUTE GLOMERULAR INJURY IN PROLIFERATIVE LUPUS NEPHRITIS
, 1989
ACQUIRED IMMUNE TOLERANCE TO CADAVERIC REL-ALLOGRAFTS
, 1989
EXPRESSION OF T-CELL RECEPTOR ANTIGENS IN MYCOSIS-FUNGOIDES AND INFLAMMATORY SKIN-LESIONS
, 1989
CLOL REARRANGEMENTS OF IMMUNOGLOBULIN GENES AND PROGRESSION TO B
, 1989
THE MAGEMENT OF BULKY MEDIASTIL HODGKINS-DISEASE
, 1989
CHARACTERIZATION OF SPLENIC STRUCTURE IN HODGKIN DISEASE BY USING RROW
, 1989
SMALL LYMPHOCYTIC LYMPHOMA
, 1989
DETECTION OF CLOL T-CELL RECEPTOR GENE REARRANGEMENTS IN THE PERIPHERAL
, 1989
NON-HODGKIN LYMPHOMA - INFLUENCE OF LYMPHOGRAPHY, CT
, 1989
PROGNOSTIC INDICATORS OF LAPAROTOMY FINDINGS IN CLINICAL STAGE-I
, 1989
VINBLASTINE, BLEOMYCIN, AND METHOTREXATE - AN EFFECTIVE ADJUVANT IN FAVORABLE HODGKINS-DISEASE
, 1988
BENIGN AND MALIGNT FORMS OF ERYTHRODERMA - CUTANEOUS IMMUNOPHENOTYPIC CHARACTERISTICS
, 1988
THE CONTEMPORARY MAGEMENT OF HODGKIN DISEASE
, 1988
COMBINED MODALITY THERAPY FOR STAGE-I-II LARGE CELL LYMPHOMA
, 1988
INTERCURRENT DEATH AFTER HODGKIN DISEASE THERAPY IN RADIOTHERAPY AND ADJUVANT MOPP TRIALS
, 1988
CLINICAL AND IMMUNOLOGICAL STUDIES OF CADAVERIC REL-TRANSPLANT RECIPIENTS GIVEN TOTAL
, 1988
NODULAR AND DIFFUSE TYPES OF LYMPHOCYTE PREDOMINCE HODGKINS-DISEASE
, 1988
T-CELL ANTIGEN DEFICIENCIES AND CLOL REARRANGEMENTS OF T
, 1988
SOLITARY PLASMACYTOMA OF BONE - TREATMENT, PROGRESSION, AND SURVIVAL
, 1987
LUPUS NEPHRITIS AFTER TOTAL LYMPHOID IRRADIATION - PERSISTENT IMPROVEMENT AND REDUCTION OF STEROID
, 1987
MYCOSIS-FUNGOIDES - MAGEMENT WITH TOPICAL NITROGEN-MUSTARD
STAGE I-IIIA NON-BULKY HODGKIN'S LYMPHOMA. IS FURTHER DISTINCTION BASED ON PROGNOSTIC FACTORS
, 2011
REVISITING LOW-DOSE TOTAL SKIN ELECTRON BEAM THERAPY IN MYCOSIS FUNGOIDES
, 2011
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
, 2010
TLI and ATG conditioning with low risk of graft-versus
, 2009
Cutaneous Peripheral T-Cell Lymphoma Associated With a Proliferation of B Cells
, 2009
Prognostic Factors in Primary Cutaneous Anapl
, 2009
Low Stage Follicular Lymphoma
, 2009
Dynamic CD8 T-Cell Responses to Tumor
, 2009
Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
, 2008
Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease
, 2008
Hodgkin disease/lymphoma.
, 2008
Tolerance and chimerism after renal and hematopoietic-cell transplantation.
, 2008
Hodgkin's lymphoma: The role of radiation in the modern combined strategies of treatment
, 2007
Impact of positive positron emission tomography on prediction of freedom from progression after
, 2007
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides
, 2007
Revised response criteria for malignant lymphoma
, 2007
Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease
, 2007
Second lymphomas and other malignant neoplasms
, 2007
Staging accuracy in mycosis fungoides
, 2006
Protective conditioning for acute graft-versus-host disease
, 2005
A technique of bone marrow collection from vertebral bodies of cynomolgus macaques
, 2005
Expression of the bcl-6 and MUM1
, 2005
Short tandem repeat analysis to monitor chimerism in Macaca fascicularis
, 2004
Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting
, 2004
Extranodal nonorbital indolent lymphomas of the head and neck
, 2004
CD30(+) cutaneous lymphoproliferative disorders
, 2003
Long-term outcome of 525 patients with mycosis fungoides
, 2003
Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial
, 2003
Gene expression profiles of cutaneous B cell lymphoma
, 2003
Topical nitrogen mustard in the management of mycosis fungoides - Update of the Stanford experience
, 2003
Mycosis fungoides: radiation therapy.
, 2003
Hodgkin's disease: A model for interdisciplinary cancer management: 2002 Janeway Lecture
, 2002
Long-term follow-up after total lymphoid irradiation in pediatric heart transplant recipients
, 2002
Mixed chimerism and immunosuppressive drug withdrawal after HLA
, 2002
Primary radiotherapy for localized orbital malt lymphoma
, 2002
Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease
, 2002
NCCN: Non-Hodgkin's lymphoma.
Natural killer/natural killer
, 2001
Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides
, 2001
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first
, 2001
High-dose therapy and autologous hematopoietic
, 2001
Long-term follow-up of patients with Stage III follicular lymphoma treated with primary
, 2001
Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced
, 2000
Management of breast cancer after Hodgkin's disease
, 2000
Toxicity of high-dose sequential chemotherapy
, 2000
What is the significance of nasal involvement in nasopharyngeal carcinoma?
, 1999
The Janeway lecture. Hodgkin's disease--finding the balance between cure and late effects.
, 1999
Epidermotropic cutaneous B-cell lymphoma mimicking mycosis fungoides
, 1999
Mycosis fungoides and the Sezary syndrome
, 1999
Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen
, 1999
Results of the 1988-1989 patterns of care study process survey for Hodgkin's disease
, 1999
Clinical characteristics and long-term outcome of patients with generalized patch and
, 1999
Role of histology in providing prognostic information in mycosis fungoides
, 1998
Mycosis fungoides in young patients: Clinical characteristics and outcome
, 1998
Radiation therapy as a component of high-dose salvage strategies in Hodgkin's disease.
, 1998
Long-term results of total lymphoid irradiation in the treatment of cardiac allograft rejection
, 1997
Fractionated total-body irradiation, etoposide
, 1997
Long-term depletion of naive T cells in patients treated for Hodgkin's disease
, 1997
Non-Hodgkin's lymphoma of the paranasal sinuses
, 1997
Stanford-Kaiser permanente G1 study for clinical stage I to IIA Hodgkin's disease
, 1997
Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies
, 1997
Comparison between conventional salvage therapy
, 1997
High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or
, 1997
Over 20 Years of Progress in Radiation Oncology: Hodgkin's Disease.
, 1997
Hodgkin's disease: Complications of therapy and excess mortality
, 1997
Gastrointestinal cancer after treatment of Hodgkin's disease
, 1997
Clinical stage IA (limited patch and plaque) mycosis fungoides - A long-term outcome analysis
, 1996
High-dose therapy and autologous bone marrow transplantation for relapsed
, 1996
Influence of preparatory regimen
, 1996
Is radiotherapy curative for stage I
, 1996
Treatment of cutaneous T-Cell lymphoma with chimeric anti-CD4 monoclonal antibody
, 1996
Hodgkin's disease - The role of radiation therapy in advanced disease
, 1996
Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease
, 1996
Long-Term Complications of Treatment and Causes of Mortality After Hodgkin's Disease.
, 1996
PROGNOSTIC FACTORS IN ERYTHRODERMIC MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME
, 1995
MULTIPLE COURSES OF HIGH-DOSE TOTAL SKIN ELECTRON
, 1995
PELVIC RELAPSE FOLLOWING SUBTOTAL LYMPHOID IRRADIATION IN EARLY-STAGE HODGKINS
, 1995
BRIEF CHEMOTHERAPY, STANFORD-V
, 1995
CD8-POSITIVE TUMOR-INFILTRATING LYMPHOCYTES INFLUENCE THE LONG-TERM SURVIVAL OF PATIENTS WITH
, 1995
FRACTIONATED TOTAL-BODY IRRADIATION, ETOPOSIDE
, 1994
TREATMENT OF EARLY-STAGE GASTRIC LYMPHOMA
, 1994
EFFECT OF TREATMENT FOR HODGKINS-DISEASE ON PULMONARY-FUNCTION - RESULTS OF A PROSPECTIVE-STUDY
, 1994
EFFECT OF FILGRASTIM (G-CSF) IN HODGKINS-DISEASE PATIENTS TREATED WITH RADIATION
, 1994
FACTORS AFFECTING LATE MORTALITY FROM HEART-DISEASE AFTER TREATMENT OF HODGKINS-DISEASE
, 1993
CARDIAC DISEASE FOLLOWING TREATMENT OF HODGKINS-DISEASE IN CHILDREN AND ADOLESCENTS
, 1993
MR-IMAGING TO DETECT CHEST
, 1993
HODGKINS-DISEASE WITH BULKY MEDIASTINAL INVOLVEMENT
, 1993
MYCOSIS-FUNGOIDES - CLINICAL AND HISTOLOGIC FEATURES, STAGING
, 1993
BREAST-CANCER AFTER TREATMENT OF HODGKINS-DISEASE
, 1993
SECONDARY LEUKEMIA AND MYELODYSPLASTIC SYNDROME AFTER TREATMENT FOR HODGKINS-DISEASE
, 1992
THE STANFORD EXPERIENCE WITH COMBINED PROCARBAZINE
, 1992
THE MANAGEMENT OF HODGKINS-DISEASE IN RELAPSE AFTER PRIMARY RADIATION-THERAPY
, 1992
COMBINED-MODALITY THERAPY FOR THE TREATMENT OF HODGKINS-DISEASE
, 1992
METASTATIC CARCINOMA IN LYMPH-NODES SIMULATING SYNCYTIAL VARIANT OF NODULAR SCLEROSING HODGKINS
, 1991
THE MANAGEMENT OF MYCOSIS-FUNGOIDES AT STANFORD - STANDARD AND INNOVATIVE TREATMENT PROGRAMS
, 1991
TOTAL LYMPHOID IRRADIATION FOR TREATMENT OF INTRACTABLE CARDIAC ALLOGRAFT-REJECTION
, 1991
OBSERVATIONS ON THE EFFECT OF CHIMERIC ANTI-CD4 MONOCLONAL
, 1991
THE STANFORD EXPERIENCE WITH HIGH-DOSE ETOPOSIDE CYTOREDUCTIVE REGIMENS AND AUTOLOGOUS BONE
, 1991
TOTAL SKIN ELECTRON-BEAM THERAPY IN THE MANAGEMENT OF MYCOSIS-FUNGOIDES
, 1991
RADIATION-THERAPY IN THE MANAGEMENT OF HODGKINS-DISEASE
, 1990
DISCORDANT EXPRESSION OF ANTIGENS BETWEEN INTRAEPIDERMAL AND INTRADERMAL T-CELLS IN MYCOSIS
, 1990
Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
, 1990
RADIATION-THERAPY IN THE MANAGEMENT OF BULKY MEDIASTINAL HODGKINS-DISEASE
, 1990
LEU-8/CD7 ANTIGEN EXPRESSION BY CD3+ T-CELLS
, 1990
PROGNOSTIC FACTORS FOR PATIENTS RELAPSING AFTER RADIOTHERAPY FOR EARLY-STAGE HODGKINS-DISEASE
, 1990
Bone marrow transplantation for hematologic malignancies: the Stanford experience.
, 1990
CUTANEOUS LYMPHOID HYPERPLASIA
, 1989
OUTCOME OF THE ACUTE GLOMERULAR INJURY IN PROLIFERATIVE LUPUS NEPHRITIS
, 1989
ACQUIRED IMMUNE TOLERANCE TO CADAVERIC RENAL-ALLOGRAFTS
, 1989
EXPRESSION OF T-CELL RECEPTOR ANTIGENS IN MYCOSIS-FUNGOIDES AND INFLAMMATORY SKIN-LESIONS
, 1989
CLONAL REARRANGEMENTS OF IMMUNOGLOBULIN GENES AND PROGRESSION TO B
, 1989
THE MANAGEMENT OF BULKY MEDIASTINAL HODGKINS-DISEASE
, 1989
CHARACTERIZATION OF SPLENIC STRUCTURE IN HODGKIN DISEASE BY USING NARROW
, 1989
SMALL LYMPHOCYTIC LYMPHOMA
, 1989
DETECTION OF CLONAL T-CELL RECEPTOR GENE REARRANGEMENTS IN THE PERIPHERAL
, 1989
NON-HODGKIN LYMPHOMA - INFLUENCE OF LYMPHOGRAPHY, CT
, 1989
EFFECTS OF IRRADIATION ON THE HUMAN IMMUNE-SYSTEM
, 1989
Current Stanford clinical trials for Hodgkin's disease.
, 1989
PROGNOSTIC INDICATORS OF LAPAROTOMY FINDINGS IN CLINICAL STAGE-I
, 1989
VINBLASTINE, BLEOMYCIN, AND METHOTREXATE - AN EFFECTIVE ADJUVANT IN FAVORABLE HODGKINS-DISEASE
, 1988
BENIGN AND MALIGNANT FORMS OF ERYTHRODERMA - CUTANEOUS IMMUNOPHENOTYPIC CHARACTERISTICS
, 1988
THE CONTEMPORARY MANAGEMENT OF HODGKIN DISEASE
, 1988
COMBINED MODALITY THERAPY FOR STAGE-I-II LARGE CELL LYMPHOMA
, 1988
INTERCURRENT DEATH AFTER HODGKIN DISEASE THERAPY IN RADIOTHERAPY AND ADJUVANT MOPP TRIALS
, 1988
TREATMENT OF LUPUS NEPHRITIS WITH TOTAL LYMPHOID IRRADIATION - OBSERVATIONS DURING A 12
, 1988
CLINICAL AND IMMUNOLOGICAL STUDIES OF CADAVERIC RENAL-TRANSPLANT RECIPIENTS GIVEN TOTAL
, 1988
POIKILODERMATOUS MYCOSIS-FUNGOIDES AND ATROPHIC LARGE
, 1988
NODULAR AND DIFFUSE TYPES OF LYMPHOCYTE PREDOMINANCE HODGKINS-DISEASE
, 1988
T-CELL ANTIGEN DEFICIENCIES AND CLONAL REARRANGEMENTS OF T
, 1988
DISSECTION OF THE MECHANISMS OF IMMUNE INJURY IN RHEUMATOID-ARTHRITIS
, 1988
The non-Hodgkin's lymphomas: pathology, staging, treatment.
, 1987
SOLITARY PLASMACYTOMA OF BONE - TREATMENT, PROGRESSION, AND SURVIVAL
, 1987
LUPUS NEPHRITIS AFTER TOTAL LYMPHOID IRRADIATION - PERSISTENT IMPROVEMENT AND REDUCTION OF STEROID
, 1987
MYCOSIS-FUNGOIDES - MANAGEMENT WITH TOPICAL NITROGEN-MUSTARD
What is Dr. Hoppe's NPI number?An National Provider Identifier (NPI) is a unique ID number that identifies doctors and healthcare providers nationwide.
Dr. Hoppe's National Provider Identifier (NPI) number is 1730221821.
What common questions do patients ask about Dr. Hoppe?
Here are answers to patients Frequently Asked Questions (FAQ’s) about Dr. Hoppe
What is Dr. Richard Hoppe's specialty?
Dr. Hoppe is a Radiation Oncologist near Pleasanton, CA.
What does a Radiation Oncologist do?
A radiological oncologist specializes in the therapeutic applications of radiant energy and its modifiers. They focus on the study and management of diseases, particularly malignant tumors.
Is this Dr. Richard Hoppe affiliated with a ranked Castle Connolly Top Hospital?
Yes, Dr. Hoppe is affiliated with Stanford Health Care - Stanford Hospital which is a Castle Connolly Top Hospital. Castle Connolly Top Hospitals are healthcare institutions recognized for their excellence in specific medical procedures and overall patient care. They are identified through a rigorous peer nomination process, evaluating factors like patient outcomes, quality of care, and expertise. The list recognizes hospitals that excel in 20 or more specific medical procedures, representing the top 25% nationwide. Castle Connolly Top Hospitals
When to see a Radiation Oncologist?: Guides for symptoms, conditions, and treatments
Understand your symptoms and know when it’s time to see a Radiation Oncologist. Explore insights from trusted medical experts on EverydayHealth.com, where you'll find the most relevant content and helpful condition guides for up-to date information about symptoms, causes, diagnosis, treatment and more. See all our health guides to find trusted information on medical conditions from our experts at Everyday Health.
Is Richard Hoppe accepting new patients in Pleasanton, CA?
Yes, Dr. Richard Hoppe is accepting new patients at this time.
Does Dr. Richard Hoppe offer online booking?
Please contact Dr. Hoppe's office for information about online booking, telehealth, or to schedule an appointment.
How can I make an appointment with Richard Hoppe?
Please contact Dr. Hoppe's office for information regarding telehealth appointment availability or for scheduling assistance.
Which board certifications does Dr. Richard Hoppe have?
Dr. Richard Hoppe is certified by the American Board of Radiology.
Other Radiation Oncologist Near Pleasanton, CA
Radiation Oncologist
Accepting patientsRadiation Oncologist
Accepting patientsRadiation Oncologist
Accepting patients